Clinical Trials Logo

Stereotactic Body Radiotherapy clinical trials

View clinical trials related to Stereotactic Body Radiotherapy.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05915481 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors

SCARCE
Start date: June 21, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this multicenter prospective single-arm phase I/II study is to study the safety and efficacy stereotactic body radiotherapy (SBRT) combined with Cadonilimab for advanced refractory malignant solid tumors. The main questions it aims to answer are: - How safe is this regimen of SBRT combined with Cadonilimab for advanced refractory malignant solid tumors? - How effective is this regimen of SBRT combined with Cadonilimab for advanced refractory malignant solid tumors? Participants will receive SBRT combined with Cadonilimab until disease progression or intolerable toxicities or death.

NCT ID: NCT05802654 Not yet recruiting - Clinical trials for Stereotactic Body Radiotherapy

Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer

USBRT-1
Start date: June 2023
Phase: N/A
Study type: Interventional

The goal of this prospective single-arm phase II study is to study the efficacy and safety of stereotactic body radiotherapy (SBRT) for early lung cancer. The main questions it aims to answer are: How effective is this regimen of SBRT for early lung cancer? How safe is this regimen of SBRT for early lung cancer?

NCT ID: NCT05286320 Not yet recruiting - Clinical trials for Unresectable Hepatocellular Carcinoma

Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

Start date: March 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

HCC patients with PVTT (main trunk or the first-degree branch) treated with the combination of pembrolizumab (Ketruda), lenvatinib (Lenvima), and SBRT.

NCT ID: NCT05136768 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)

LM-HNSCC
Start date: December 2021
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of combination of Sintilimab and SBRT on the basis of platinum-containing chemotherapy as the first-line treatment of limited metastatic head and neck squamous cell carcinoma (LM-HNSCC).